Rejuveron Life Sciences AG is a Swiss integrated biotechnology platform company that develops and invests in drugs and technologies which have the potential to improve longevity. As well as providing startup-coaching and incubator lab space, they provide direct investment in promising means to improve health aging, with the ultimate goal of increasing human healthspan.
DEFTA Partners is a
capital firm founded in the 1980s and has offices in San Francisco and Tokyo - DEFTA
Healthcare Technologies, the firm's newly formed fund, invests in seed and early
stage companies developing advanced therapeutics and digital health in the USA,
Japan, Israel, and beyond - the current investments in healthcare include endogena
therapeutics, Orig3n, Two Pore Guys, Lifeguard Health Networks, and Graftworx. DEFTA
Partners also supports the annual World Alliance Forum in San Francisco, a premier,
international conference focused on game changing healthcare innovations and
The Centre for Commercialization of
Regenerative Medicine (CCRM) is a not-for-profit, public-private consortium
supporting the development of foundational technologies that accelerate the
commercialization of cell and gene therapies, and regenerative medicine
These technologies have the potential to transform health care, with the promise to
treat, manage and perhaps cure some of the most debilitating and costly diseases in
the world today. However, many new potentially life-changing cell, gene and
regenerative medicine-based treatments never reach patients because they are not
successfully moved from the laboratory to the clinic.
Canadian scientific excellence in stem cells, bioengineering and biomaterials
combined with existing infrastructure positions CCRM to coordinate product
development and commercialization in a capital-efficient manner.